Literature DB >> 23838947

TEM-1 β-lactamase as a source of resistance to sulbactam in clinical strains of Acinetobacter baumannii.

Lenka Krizova1, Laurent Poirel, Patrice Nordmann, Alexandr Nemec.   

Abstract

OBJECTIVES: Sulbactam is well known to have clinically relevant intrinsic activity against Acinetobacter baumannii. Although secondary resistance to this drug has long been reported in acinetobacters, virtually nothing is known about its molecular basis. The aim of this study was to test the hypothesis that β-lactamase TEM-1 is responsible for sulbactam resistance in A. baumannii.
METHODS: Seventeen clinical strains of A. baumannii were selected to represent different combinations of quantitative susceptibilities to sulbactam and molecular typing characteristics. The strains were screened by PCR for the presence of the blaTEM-1 gene and its variants. Amplicons encompassing the blaTEM genes, including their promoters, were sequenced. The expression and copy number of the blaTEM genes were assessed using semi-quantitative real-time PCR. Transfer of the blaTEM-1 gene into a susceptible A. baumannii strain was achieved by electroporation.
RESULTS: Six strains were negative for the blaTEM gene and had sulbactam MICs of 0.5-1.0 mg/L, 10 strains harboured blaTEM-1 and showed MICs ≥ 8.0 mg/L, except for one strain with an MIC of 2 mg/L, while the remaining strain carried blaTEM-19 and had an MIC of 1 mg/L. The level of blaTEM-1 expression positively correlated with the MICs of sulbactam (r = 0.92). Promoter P4 was linked to the blaTEM gene in all strains except for a P3-carrying strain (an MIC of 2 mg/L). Transformation of the susceptible A. baumannii strain with blaTEM-1 resulted in a 64-fold increase in sulbactam MIC and in resistance to ticarcillin and piperacillin, but no change in susceptibility to broad-spectrum generation cephalosporins, aztreonam or carbapenems.
CONCLUSIONS: The results presented suggest that TEM-1 represents a clinically relevant mechanism of sulbactam resistance in A. baumannii.

Entities:  

Keywords:  gene expression; mechanisms of resistance; multidrug resistance; transformation

Mesh:

Substances:

Year:  2013        PMID: 23838947     DOI: 10.1093/jac/dkt275

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  30 in total

1.  Molecular Epidemiology and Mechanism of Sulbactam Resistance in Acinetobacter baumannii Isolates with Diverse Genetic Backgrounds in China.

Authors:  Yunxing Yang; Ying Fu; Peng Lan; Qingye Xu; Yan Jiang; Yan Chen; Zhi Ruan; Shujuan Ji; Xiaoting Hua; Yunsong Yu
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

Review 2.  Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options.

Authors:  Yohei Doi; Gerald L Murray; Anton Y Peleg
Journal:  Semin Respir Crit Care Med       Date:  2015-02-02       Impact factor: 3.119

3.  In Vitro Activity of Sulbactam-Durlobactam against Acinetobacter baumannii-calcoaceticus Complex Isolates Collected Globally in 2016 and 2017.

Authors:  Sarah M McLeod; Samir H Moussa; Meredith A Hackel; Alita A Miller
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

4.  OXA-23 Is a Prevalent Mechanism Contributing to Sulbactam Resistance in Diverse Acinetobacter baumannii Clinical Strains.

Authors:  Yunxing Yang; Qingye Xu; Tingting Li; Ying Fu; Yue Shi; Peng Lan; Dongdong Zhao; Qiong Chen; Zhihui Zhou; Yan Jiang; Anton Y Peleg; Yunsong Yu
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

5.  Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii.

Authors:  William F Penwell; Adam B Shapiro; Robert A Giacobbe; Rong-Fang Gu; Ning Gao; Jason Thresher; Robert E McLaughlin; Michael D Huband; Boudewijn L M DeJonge; David E Ehmann; Alita A Miller
Journal:  Antimicrob Agents Chemother       Date:  2015-01-05       Impact factor: 5.191

6.  ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii.

Authors:  Thomas F Durand-Réville; Satenig Guler; Janelle Comita-Prevoir; Brendan Chen; Neil Bifulco; Hoan Huynh; Sushmita Lahiri; Adam B Shapiro; Sarah M McLeod; Nicole M Carter; Samir H Moussa; Camilo Velez-Vega; Nelson B Olivier; Robert McLaughlin; Ning Gao; Jason Thresher; Tiffany Palmer; Beth Andrews; Robert A Giacobbe; Joseph V Newman; David E Ehmann; Boudewijn de Jonge; John O'Donnell; John P Mueller; Rubén A Tommasi; Alita A Miller
Journal:  Nat Microbiol       Date:  2017-06-30       Impact factor: 17.745

7.  Frequency and Mechanism of Spontaneous Resistance to Sulbactam Combined with the Novel β-Lactamase Inhibitor ETX2514 in Clinical Isolates of Acinetobacter baumannii.

Authors:  Sarah M McLeod; Adam B Shapiro; Samir H Moussa; Michele Johnstone; Robert E McLaughlin; Boudewijn L M de Jonge; Alita A Miller
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

8.  Spectroscopic analysis and docking simulation on the recognition and binding of TEM-1 β-lactamase with β-lactam antibiotics.

Authors:  Jianting Yang; Qian Li; Liujiao Bian
Journal:  Exp Ther Med       Date:  2017-07-31       Impact factor: 2.447

9.  Characterization and distribution of drug resistance associated β-lactamase, membrane porin and efflux pump genes in MDR A. baumannii isolated from Zhenjiang, China.

Authors:  Huijian Yang; Lan Huang; Prince Amoah Barnie; Zhaoliang Su; Zuhuang Mi; Jianguo Chen; Vasudevan Aparna; Dinesh Kumar; Huaxi Xu
Journal:  Int J Clin Exp Med       Date:  2015-09-15

Review 10.  Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections.

Authors:  J Alexander Viehman; M Hong Nguyen; Yohei Doi
Journal:  Drugs       Date:  2014-08       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.